A new study has revealed that small cell lung cancer (SCLC) is likely to begin in basal stem cells rather than in neuroendocrine cells. This marks a major shift in understanding this deadly disease of lung cancer. The study led by Duke scientists has been published in the Journal Nature. It shows basal cells can give rise to tumors in both classic neuroendocrine form and a tuft-like form. Scientists have always thought that SCLC begins in specialized lung cells called neuroendocrine cells but this study reveals something else.
“Our models, for the first time, reflect the full complexity of the disease,” Trudy G. Oliver said, “allowing us to study and target its most dangerous forms.” In this study, they use genetically engineered mice, 3D tumor organoids and human SCLC tumors. The tuft-like form is associated with poor patient outcomes. They also found that tuft-like tumors were only triggered when genetic changes were introduced into basal cells. By finding that basal cells can form tumor, researchers can now explore strategies to prevent lung cancer before it evades the immune system.
According to the researchers, this discovery creates the first accurate lab models of tuft-like form of SCLC. This new model allows for advancement in the study of early detection and targeted therapies. This will help to explore how the immune system interacts with these basal cells before they transform into aggressive lung cancer.
The research was funded by the Duke Science and Technology Scholar initiative, the National Institutes of Health through National Cancer Institute grants and the Cancer Center Support Grant.
The information shared in this blog is for educational purposes only. You should always consult with your healthcare provider for any medical needs.
Subscribe to our newsletter or follow us on Facebook or X today to stay informed and never miss an update!